根據 位華爾街分析師的預測,Yubo International Biotech Ltd 的收入預期範圍從 $ 到 $
Yubo International Biotech Ltd 的盈利品質評分是多少?
Yubo International Biotech Ltd 的盈利品質評分為 B+/54.022205。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Yubo International Biotech Ltd 何時發布財報?
Yubo International Biotech Ltd 的下一份財報預計在 發布
Yubo International Biotech Ltd 的預期收益是多少?
根據華爾街分析師的預測,Yubo International Biotech Ltd 的預期收益為 $
Yubo International Biotech Ltd 是否超出收益預期?
Yubo International Biotech Ltd 最近的收益為 $, 預期。
關鍵數據
前收市價
$0.0151
開盤價
$0.0104
當日範圍
$0.0104 - $0.0151
52週區間
$0.0079 - $0.1776
交易量
10.0K
平均成交量
3.5K
股息收益率
--
每股盈餘 (TTM)
-0.01
市值
$2.5M
什麼是 YBGJ?
Yubo International Biotech Ltd. engages in the supply of products that process, store, and administer therapeutic doses of endometrial stem cells for the treatment of disease and injuries. The company is headquartered in Beijing, Beijing and currently employs 18 full-time employees. The firm focuses on the research and development and application of endometrial stem cells and offers its products and services under the brand VIVCELL. The Company’s product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. The firm also offers stem cell related services including cell testing and health management consulting services.